# GETUG-AFU 17

Source: https://onco.cc/trials/getug-afu-17/  
OnCo record `getug-afu-17` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The French version of the same question, and the same answer: treating everyone straight after surgery does not help, and it doubles the rate of lasting bladder and erection problems.

## Summary

GETUG-AFU 17 enrolled 424 men at 46 French hospitals with pT3a, pT3b or pT4a disease and positive surgical margins after radical prostatectomy, randomised 1:1 to immediate adjuvant radiotherapy or delayed salvage radiotherapy at biochemical relapse. All men received 6 months of triptorelin. Enrolment was stopped early on the recommendation of the independent data monitoring committee because event rates were unexpectedly low; 718 had been planned.

At a median 75 months, 205 of 212 men (97 percent) in the adjuvant group started treatment, against 115 of 212 (54 percent) in the salvage group. Five-year event-free survival was 92 percent (95 percent confidence interval 86 to 95) with adjuvant radiotherapy and 90 percent (85 to 94) with salvage, hazard ratio 0.81 (0.48 to 1.36, log-rank p=0.42).

The toxicity difference was large. Late grade 2 or worse genitourinary adverse events occurred in 58 of 212 men (27 percent) after adjuvant radiotherapy against 14 of 212 (7 percent) after salvage (p<0.0001), and late erectile dysfunction of grade 2 or worse in 60 of 212 (28 percent) against 17 of 212 (8 percent) (p<0.0001). Acute grade 3 or worse effects were rare in both arms, six and four men respectively.

The authors were candid that the analysis lacked statistical power, which is why the ARTISTIC meta-analysis was designed in advance to pool the three trials.

## Fields

- Kind: Trial
- Status: mixed
- Last checked: 2026-09-25
- Also known as: GETUG-AFU 17; GETUG 17
- Registry id: NCT00667069
- Phase: 3
- Setting: pT3a, pT3b or pT4a prostate cancer with positive surgical margins after radical prostatectomy: immediate adjuvant radiotherapy against delayed salvage radiotherapy at biochemical relapse, both with 6 months of triptorelin, with event-free survival as the primary endpoint
- Sponsor: UNICANCER, funded by the French Health Ministry and Ipsen
- Enrolled: 424
- Result: Five-year event-free survival 92 percent with adjuvant against 90 percent with salvage radiotherapy (hazard ratio 0.81, 95 percent confidence interval 0.48 to 1.36); late grade 2 or worse genitourinary toxicity 27 against 7 percent and erectile dysfunction 28 against 8 percent.
- Outcomes: Event-free survival at 5 years: Adjuvant radiotherapy 92% vs Delayed salvage radiotherapy 90%, HR 0.81; Late grade 2 or worse erectile dysfunction: Adjuvant radiotherapy 28% vs Delayed salvage radiotherapy 8%
- Replication: RADICALS-RT and RAVES found the same, and all three were pooled in ARTISTIC.

## Sources

- ClinicalTrials.gov NCT00667069: https://clinicaltrials.gov/study/NCT00667069
- GETUG-AFU 17 (Lancet Oncology 2020): https://doi.org/10.1016/S1470-2045(20)30454-X

## Connected records

- cancers: [Biochemical recurrence of prostate cancer](https://onco.cc/cancers/prostate-bcr/), [Localised prostate cancer, high and very high risk](https://onco.cc/cancers/prostate-high-risk/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Androgen deprivation & AR pathway inhibitors](https://onco.cc/technologies/androgen-deprivation/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Triptorelin](https://onco.cc/drugs/triptorelin/)
- companies: [Ipsen](https://onco.cc/companies/ipsen/), [UNICANCER](https://onco.cc/companies/unicancer/)
- terms: [Biochemical recurrence (BCR)](https://onco.cc/terms/biochemical-recurrence/), [Quality of life and patient-reported outcomes (QoL, PRO)](https://onco.cc/terms/qol-pro/), [Radical prostatectomy](https://onco.cc/terms/prostatectomy/), [Salvage therapy](https://onco.cc/terms/salvage-therapy/)
- trials: [ARTISTIC meta-analysis](https://onco.cc/trials/artistic-meta-analysis/), [RADICALS-RT](https://onco.cc/trials/radicals-rt/), [RAVES (TROG 08.03/ANZUP)](https://onco.cc/trials/raves/)

---
JSON: https://onco.cc/api/v1/entities/getug-afu-17.json